Immune checkpoint inhibitors: new strategies to checkmate cancer

Summary Immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte‐associated protein‐4 (CTLA‐4) or programmed cell death protein 1 (PD‐1) receptors have demonstrated remarkable efficacy in subsets of patients with malignant disease. This emerging treatment modality holds great promise for future cancer treatment and has engaged pharmaceutical research interests in tumour immunology. While ICIs can induce rapid and durable responses in some patients, identifying predictive factors for effective clinical responses has proved challenging. This review summarizes the mechanisms of action of ICIs and outlines important preclinical work that contributed to their development. We explore clinical data that has led to disease‐specific drug licensing, and highlight key clinical trials that have revealed ICI efficacy across a range of malignancies. We describe how ICIs have been used as part of combination therapies, and explore their future prospects in this area. We conclude by discussing the incorporation of these new immunotherapeutics into precision approaches to cancer therapy. Immune checkpoint inhibitors (ICIs) targeting CTLA‐4 or PD‐1 axes have demonstrated remarkable efficacy in patients with malignant disease. This emerging treatment holds great promise for future cancer treatment, often inducing rapid and durable responses in patients. This review summarises the mechanisms of action of ICIs, outlines important pre‐clinical work, analyzes key clinical data from a range of malignancies, and explores their future prospects in this area.